Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
$2.52
$1.61
$4.40
$45.72M2.2481,367 shs63,385 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.07
-3.7%
$12.61
$5.22
$27.38
$157.73M0.43146,569 shs132,390 shs
MediWound Ltd. stock logo
MDWD
MediWound
$18.99
-0.5%
$19.36
$13.49
$24.00
$206.32M0.3890,992 shs74,898 shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$2.94
-1.0%
$3.26
$2.65
$9.55
$164.35M0.82480,330 shs616,564 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
0.00%0.00%0.00%0.00%-32.59%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-3.67%-5.41%-4.66%-17.67%+78.55%
MediWound Ltd. stock logo
MDWD
MediWound
-0.52%-7.32%-6.77%+13.99%+41.08%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-1.01%-11.18%+0.68%-20.97%-63.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.9664 of 5 stars
3.50.01.72.72.61.71.3
MediWound Ltd. stock logo
MDWD
MediWound
1.5855 of 5 stars
3.51.00.00.00.00.80.6
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.9196 of 5 stars
3.61.00.04.62.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
0.00
N/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50152.69% Upside
MediWound Ltd. stock logo
MDWD
MediWound
3.00
Buy$31.8067.46% Upside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39355.44% Upside

Current Analyst Ratings Breakdown

Latest ALRN, MDWD, LFVN, and VYGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$34.00
5/22/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00 ➝ $31.00
5/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
4/8/2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.76$0.85 per share14.21$2.05 per share5.89
MediWound Ltd. stock logo
MDWD
MediWound
$20.22M10.15N/AN/A$2.89 per share6.57
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.03N/AN/A$5.49 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6917.49N/A4.12%34.67%15.24%8/27/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest ALRN, MDWD, LFVN, and VYGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.49%N/A26.09%3 Years
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A

Latest ALRN, MDWD, LFVN, and VYGR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/A
3.30
3.30
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
MediWound Ltd. stock logo
MDWD
MediWound
N/A
2.15
1.99
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
90.89%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
5.10%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
4.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
921.67 million20.56 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.81 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million52.83 millionOptionable

Recent News About These Companies

Voyager Technologies Soars with IPO Success
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO
Voyager Therapeutics, Inc. stock logo
Brokers Issue Forecasts for VYGR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aileron Therapeutics stock logo

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.07 -0.46 (-3.67%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$12.10 +0.03 (+0.25%)
As of 06/23/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MediWound stock logo

MediWound NASDAQ:MDWD

$18.99 -0.10 (-0.52%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$20.01 +1.02 (+5.37%)
As of 06/23/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$2.94 -0.03 (-1.01%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$2.89 -0.05 (-1.70%)
As of 06/23/2025 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.